Can You Have MMN With Negative Anti-GM1 Antibodies?
At a Glance
Yes. A negative anti-GM1 antibody test does not rule out multifocal motor neuropathy because antibodies are found in about half of people with MMN. Neurologists rely on the pattern of weakness, examination, and nerve conduction studies, with other tests used to exclude similar conditions.
In this answer
3 sections
Yes, you can absolutely have Multifocal Motor Neuropathy (MMN) even if your blood test for anti-GM1 antibodies is negative. In fact, depending on the laboratory and the group of patients studied, between 46% and 57% (roughly half) of people with confirmed MMN do not have these antibodies in their blood [1][2][3].
A negative test result does not rule out the disease, nor does it mean your symptoms are imaginary. It simply means your neurologist cannot use this specific blood test to confirm MMN and will instead rely on your physical examination and specialized nerve tests to make a diagnosis and rule out other potential causes [4].
The Role of Anti-GM1 Antibodies
Anti-GM1 antibodies are immune system proteins that mistakenly bind to a specific molecule (a ganglioside) found on the surface of motor nerve cells. While finding these antibodies can support an MMN diagnosis, their exact role in causing the disease is not fully understood [4]. Because they are found in only about half of patients, neurologists consider them a “supportive biomarker” rather than a strict requirement for having the disease [2][4].
How Your Doctor Confirms MMN
Because the blood test is only one piece of the puzzle, a negative result means your doctor will focus closely on your physical symptoms and your nerve activity. MMN is a clinical diagnosis, which means your doctor looks at your overall history, examination, and test results rather than relying on a single lab value.
- The Clinical Examination: Your doctor will look for the classic physical pattern of MMN. This typically involves slowly progressive, asymmetric weakness (meaning it is noticeably worse on one side of the body than the other) that predominantly affects the arms and hands [1]. MMN is a motor nerve disease, meaning it primarily affects your strength. While minor sensory symptoms can sometimes occur, significant numbness or tingling usually points toward a different diagnosis [1][4].
- Nerve Conduction Studies (NCS): This is the most important test for evaluating MMN. Small electrical impulses are used to measure how well your nerves send signals to your muscles. The neurologist is looking for a motor conduction block—a substantial drop in the electrical signal’s strength as it travels down the nerve fiber [4][5]. To strongly support an MMN diagnosis, this block must be found in locations other than common “pinch points” (like the wrist or elbow, where nerves are often naturally compressed) [5]. However, it can sometimes be difficult to capture a block early in the disease or if there is advanced nerve damage.
- Ruling Out Other Conditions: A negative antibody test makes it especially important to rule out conditions that can mimic MMN [6]. Your doctor will use your NCS results and clinical exam to distinguish MMN from other issues, such as a pinched nerve in your spine (radiculopathy), a different autoimmune neuropathy like CIDP, or Motor Neuron Disease (which typically involves different reflexes and more widespread symptoms) [6][7].
- Imaging as an Adjunct: If your NCS results are borderline or unclear, doctors may sometimes use imaging. A nerve ultrasound or specialized MRI can look for physical swelling in the nerves to provide supportive information [8][9]. These are not routine confirmation tests and a normal scan does not rule out MMN, but they can occasionally help clarify the diagnosis [10].
Treatment Considerations
It is completely normal to feel anxious when a test comes back negative, especially when you are searching for answers. However, if your neurologist suspects MMN based on your physical exam and your nerve conduction studies, a negative antibody test should not stop you from receiving a diagnosis.
If your clinical picture strongly points to MMN, your doctor may discuss a treatment trial, such as IVIG (Intravenous Immunoglobulin). IVIG is aimed at improving or stabilizing your strength. It is a medical treatment, not a diagnostic test, so if a trial is recommended, you and your doctor should agree beforehand on exactly how your strength will be measured, what the expected timeframe for improvement is, and what the next steps will be if your symptoms do not improve.
(Note: If you experience rapidly worsening weakness, new trouble breathing or swallowing, or sudden severe functional decline, contact your clinical team promptly, as these symptoms are not typical of the slowly progressive pattern of MMN.)
Common questions in this guide
Can I have multifocal motor neuropathy if my anti-GM1 antibody test is negative?
How do doctors diagnose MMN when the antibody test is negative?
What does motor conduction block mean on a nerve test?
How is MMN distinguished from CIDP or motor neuron disease?
Can I receive IVIG for MMN if anti-GM1 antibodies are negative?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About testing
Should I ask for nerve conduction studies to help confirm a diagnosis?
Imaging options
Could a nerve ultrasound or MRI help if my nerve study results are unclear?
Treatment planning
Could we agree on how my strength would be measured if IVIG is considered?
Related questions
Show more
Get notified when new evidence is published on Multifocal motor neuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
Multifocal Motor Neuropathy: A Narrative Review.
Claytor B, Polston D, Li Y
Muscle & nerve 2025; (71(4)):512-534 doi:10.1002/mus.28349.
PMID: 39936246 - 2
Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment.
Löscher WN, Oberreiter EM, Erdler M, et al.
Journal of neurology 2018; (265(12)):2834-2840 doi:10.1007/s00415-018-9071-9.
PMID: 30259176 - 3
Multifocal motor neuropathy in Japan: A nationwide survey on prevalence, clinical profiles, and treatment.
Aotsuka Y, Misawa S, Suichi T, et al.
Muscle & nerve 2024; (70(5)):1027-1033 doi:10.1002/mus.28251.
PMID: 39253889 - 4
Revisiting multifocal motor neuropathy: mechanisms, diagnosis and future directions.
Dubuisson NJ, Rajabally YA, Philips C, et al.
Brain : a journal of neurology 2026; doi:10.1093/brain/awag260.
PMID: 42522566 - 5
Refining Electrophysiological Criteria in CIDP and MMN: Toward a Unified Definition of Motor Conduction Block and Proximal Temporal Dispersion.
Gallo C, Fasano C, Fonseca A, et al.
European journal of neurology 2026; (33(8)):e70739 doi:10.1111/ene.70739.
PMID: 42613787 - 6
Clinical and electrophysiological features for differentiating MMN from hand-onset ALS.
Fang SY, Jih KY, Chao YC, et al.
Journal of the Chinese Medical Association : JCMA 2026; (89(6)):437-444 doi:10.1097/JCMA.0000000000001387.
PMID: 42115814 - 7
A Practical Guide to Identify Patients With Multifocal Motor Neuropathy, a Treatable Immune-Mediated Neuropathy.
Allen JA, Clarke AE, Harbo T
Mayo Clinic proceedings. Innovations, quality & outcomes 2024; (8(1)):74-81 doi:10.1016/j.mayocpiqo.2023.12.002.
PMID: 38283096 - 8
Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy.
Grimm A, Décard BF, Athanasopoulou I, et al.
Journal of neurology 2015; (262(4)):870-80 doi:10.1007/s00415-015-7648-0.
PMID: 25626722 - 9
Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for differentiation of demyelinating inflammatory and hereditary neuropathies.
Grimm A, Vittore D, Schubert V, et al.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2016; (127(7)):2618-24.
PMID: 27291881 - 10
Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database.
Doneddu PE, Gentile L, Cocito D, et al.
European journal of neurology 2024; (31(5)):e16248 doi:10.1111/ene.16248.
PMID: 38376074
This page is for informational purposes only and is not medical advice. It explains how neurologists evaluate suspected MMN when anti-GM1 antibodies are negative; discuss your results and treatment with your neurologist.